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SOCS1 mimetics and antagonists: a
complementary approach to positive
and negative regulation of immune
function
Chulbul M. I. Ahmed, Joseph Larkin III and Howard M. Johnson*
Department of Microbiology and Cell Science, University of Florida, Gainesville, FL, USA
Suppressors of cytokine signaling (SOCS) are inducible intracellular proteins that play
essential regulatory roles in both immune and non-immune function. Of the eight known
members, SOCS1 and SOCS3 in conjunction with regulatory T cells play key roles in
regulation of the immune system. Molecular tools such as gene transfections and siRNA
have played amajor role in our functional understanding of the SOCS proteins where a key
functional domain of 12-amino acid residues called the kinase inhibitory region (KIR) has
been identified on SOCS1 and SOCS3. KIR plays a key role in inhibition of the JAK2 tyro-
sine kinase, which in turn plays a key role in cytokine signaling. A peptide corresponding
to KIR (SOCS1-KIR) bound to the activation loop of JAK2 and inhibited tyrosine phospho-
rylation of STAT1α transcription factor by JAK2. Cell internalized SOCS1-KIR is a potent
therapeutic in the experimental allergic encephalomyelitis (EAE) mouse model of multiple
sclerosis and showed promise in a psoriasis model and a model of diabetes-associated
cardiovascular disease. By contrast, a peptide, pJAK2(1001–1013), that corresponds to
the activation loop of JAK2 is a SOCS1 antagonist. The antagonist enhanced innate and
adaptive immune response against a broad range of viruses including herpes simplex
virus, vaccinia virus, and an EMC picornavirus. SOCS mimetics and antagonists are thus
potential therapeutics for negative and positive regulation of the immune system.
Keywords: immune therapy, SOCS mimetics, SOCS antagonist, antivirals, poxvirus
Introduction
The immune system consists of both positive and negative regulators that act in harmony tomaintain
immune homeostasis. A family of intracellular proteins called suppressors of cytokine signaling
(SOCS) negatively regulates both receptor-associated tyrosine kinases such as the JAKs and receptor
tyrosine kinases such as EGF receptor (1–5). The JAKs play a key role in cytokine signaling by phos-
phorylation and activation of transcription factors called STATs (6). As these tyrosine kinases thus
play key roles in cytokine, growth factor, and hormone signaling, various SOCSplay an indispensable
role in regulation of their activities (7, 8). The SOCS group has a membership of eight, SOCS1,
SOCS2, SOCS3, SOCS4, SOCS5, SOCS6, SOCS7, and SH2 cytokine-inducible protein. SOCS1 is
important for its regulation of the JAK2 tyrosine kinase as well as the related kinases TYK2 and JAK1
(2, 8). Receptor tyrosine kinases such as EGF receptor are also regulated by SOCS1 (4). Deficiency
in SOCS1 as per knockout of the gene (SOCS1 / ) results in a neonatal fatal inflammatory disease
where the cytokine gamma interferon (IFNγ) is the chief cause of the resultant pathology (9).
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Among other regulatory players in the immune response, reg-
ulatory T cells (Tregs), particularly so-called natural Tregs, also
play a key role in immune homeostasis (10–13). We and others
have shown that there is an obligatory cross-talk between SOCS1
and peripheral Tregs where SOCS1 plays a key role inmaintaining
Treg stability (12–14). Molecular genetics via transfections and
siRNA approaches have generally been the only way to regulate
the intracellular activities of SOCS such as SOCS1 (15). SOCS1
protein has not lent itself to a functional approach to immune
regulation for various technical reasons; however, SOCS3 protein
has been obtained and used in structure studies of SOCS3/JAK2
interaction (16). We have, by contrast, been able to develop small
peptide mimetics and antagonists of SOCS1 (17–19). This has
been achieved for the following reasons. First, we have identified
one of the key regions of the SOCS1 molecule called the kinase
inhibitory region (KIR) as a target for development of SOCS1
mimetics (17). Having done that, we focused on the JAK2 tyrosine
kinase activation or autocatalytic region, which interacts with
the SOCS1 mimetic as a target for development of SOCS1 (and
SOCS3) antagonists (18). Second, it has been well established
among the structural biology community that many key proteins,
particularly those associated with signaling, lack stable tertiary
structure yet carry out numerous biological functions (20). The
KIRs of SOCS1 and SOCS3 are slightly homologous and solution
structure of SOCS3 has shown that KIR is unstructured (21).
The activation loop of JAK2 is similarly unstructured (20). We
reasoned that unstructured sequences of proteins are candidates
for intrinsic function independent of other regions of the proteins.
With this understanding, we were not conceptually restricted in
the development of small peptide mimetics and antagonists of
SOCS1. We show here that the SOCS1 mimetics are effective in
treatment of autoimmune and inflammatory disorders and that
the SOCS1 antagonists enhance the immune response for effec-
tive handling of viral infections by tilting immune homeostasis
toward increased immune activity. This review/perspective thus
demonstrates the success of our approach.
Development of SOCS1 Mimetics
We focused on the activation loop of JAK2 to first develop
inhibitors of its enzymatic activity independent of the physio-
logical regulation of JAKs by SOCS. The autophosphorylation or
activation loop region of human JAK2 became a focal point in our
development of SOCS1mimetics. The amino acid sequence of this
region is 1001LPQDKEYYKVKEP for human JAK2 and is depicted
symbolically as pJAK2(1001–1013) with the p of pJAK2 indicative
of phosphorylation of tyrosine 1007, reflecting its activation state
(22). Our first SOCS1 mimetic was developed using an algorithm
based on hydropathic complementarity to the JAK2 activation
loop (23, 24). We thus synthesized a 12-amino acid peptide,
WLVFFVIFYFFR, and determined that it specifically bound the
activation loop of JAK2, inhibited IFNγ activation of JAK2 and
STAT1α as well as phosphorylation of the IFNγ receptor subunit
IFNGR1 (4). Functionally, the tyrosine kinase inhibitory peptide
(Tkip) inhibited antiviral activity of IFNγ as well as upregulation
of MHC class I molecules on fibroblast cells (4). When compared
to the KIR residues of SOCS1, Tkip showed homology with the
KIR residues F56, F59, and R60 (22). F59 has been shown to
be critical for binding of SOCS1 to activated JAK2 (22). The
sequences of Tkip and SOCS1-KIR are shown aligned in Table 1
to illustrate the critical residues.
The KIR region of SOCS1 and SOCS3 are located in the N-
terminus of the proteins and are adjacent to a similarly short
extended SH2 sequence (ESS). C-terminus to ESS is the SRC
homology 2 (SH2) domain, followed by the 40 amino acid SOCS
box (3). The SOCS box is shared in all SOCS proteins, in contrast
to the restriction of KIR to SOCS1 and SOCS3. The SOCS box
is involved in proteasomal degradation of the associated tyrosine
kinases. Thus, SOCS1-KIR only inhibits JAK2 kinase activity,
while the intact SOCS1 protein inhibits JAK2 kinase activity and
initiates its proteasomal degradation.
Peptides corresponding to the 12-amino acid KIR (SOCS1-
KIR) and the adjacent extended SH2 sequence (ESS) regions of
SOCS1 were compared to Tkip for binding to JAK2 activation
loop, pJAK2(1001–1013). Both Tkip and SOCS1-KIR, but not
the ESS peptide, bound to pJAK2(1001–1013). Tkip, thus, fortu-
itously led us to the KIR region of SOCS1 as a potential SOCS1
mimetic. Dose–response competitive binding suggested that Tkip
and SOCS1-KIR similarly recognized the activation loop as per
the pJAK2(1001–1013) peptide. Tkip inhibited JAK2 autophos-
phorylation; SOCS1-KIR did not. Both inhibited STAT1α acti-
vation, IFNγ activation of macrophages, and antigen-specific
lymphocyte proliferation. The use of the SOCS1 mimetics in
treatment of autoimmune diseases in mouse models is presented
under a separate section below.
Remarkable progress has been made in structure studies of
SOCS3, which also contains a KIR region in its N-terminus (3).
Care should be exercised, however, in the extrapolation of the
structure findings with SOCS3 to SOCS1, particularly concern-
ing KIR. In crystallographic determination of the structure of
SOCS3/JAK2 complex, it was shown that KIR was required for
complex formation, but the SOCS3-KIR peptide alone did not
block JAK2 kinase activity (16). In the same experiment, however,
the authors did show that SOCS1-KIR blocked JAK2 activity,
which confirms our original observation that SOCS1-KIR peptide
mimics SOCS1 protein in inhibiting JAK2 (18). For SOCS3, KIR is
thus described as a “pseudosubstrate” in that it is thought to block
substrate access to the activation loop of JAK2 (16). Since SOCS3-
KIR is required for SOCS3 binding to JAK2, it seems reasonable
to suppose that it is binding to something on JAK2. Since the
TABLE 1 | SOCS1 mimetics and antagonists.
Peptide Function Sequence Reference
Tkip SOCS1 mimetic WLVFFVIFYFFR (4)
SOCS1-KIR SOCS1 mimetic 53DTHFRTFRSHSDYRRI (18)
SOCS3-KIR Pseudosubstrate 20LRLKTFSSKSEYQLVV (16)
pJAK2(1001–1013) SOCS1 antagonist 1001LPQDKEpYYKVKEP (18)
Tyrosine kinase inhibitory peptide (Tkip) was developed based on hydropathic comple-
mentarity to the activation loop of the tyrosine kinase JAK2 (16). pJAK2(1001–1013) is a
peptide that corresponds to the activation loop of JAK2. pJAK2 indicates the activation
state with phosphorylated Y1007. The kinase inhibitory region (KIR) of human SOCS1
is represented by peptide SOCS1-KIR. The KIR region of SOCS3 is represented by the
peptide SOCS3-KIR. Tkip and SOCS1-KIR are aligned to illustrate homologous residues
in bold. F56 and F59 have been shown to be critical for SOCS1 binding to JAK2 (22).
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crystallographic studies showed that unstructured KIR and JAK2
activation loop were in close proximity, it is possible that SOCS3-
KIR could bind to the activation loop in such amanner that would
not block JAK2 kinase activity, but would block substrate access,
possibly in concert with another region(s) of SOCS3.
Development of SOCS1 Antagonist
Both SOCS1 and SOCS3-KIR are required for the binding of
those SOCS to JAK2 as well as TYK2 and JAK1 tyrosine kinases
(3). As indicated, SOCS1-KIR can inhibit JAK2 kinase activity,
and although SOCS3-KIR functions as a pseudosubstrate, it does
not inhibit JAK2 in the absence of other domains of SOCS3. In
any event, both the KIRs of SOCS1 and SOCS3 are intimately
associatedwith the activation loop of JAK2 as reflected in the JAK2
peptide of Table 1. In the activated state, the JAK2 kinase domain
is associated with the pseudokinase domain, suggesting that this
association is responsible for JAK2 autoinhibition. Importantly,
the activation loop is in the kinase domain and phosphorylation of
Y1007 in the activation loop is associated with activation of JAK2
(16). Thus, identification of the SOCS1-KIR binding site on JAK2
leads conceptually to development of a SOCS1 antagonist for
enhancement of the immune response. As indicated above, JAK2
activation loop peptide, pJAK2(1001–1013), binds SOCS1-KIR.
Cell-penetrating lipo-pJAK2(1001–1013) increased IFNγ and IL-
6 biological activity by blocking SOCS1 function in cells (18).
Consistent with increasing IFNγ activity, JAK2 activation loop
peptide enhanced IFN activity against herpes simplex virus-1
(HSV-1) in keratinocytes (25). The anti-HSV-1 effects of the
SOCS1 antagonist is expanded upon in the antiviral section below
with respect to other viruses in both cultures and animal models.
The development of SOCS1 mimetic and antagonist is illustrated
in Figure 1.
Cross-Talk Between SOCS1 and
Regulatory T Cells
Forkhead box P3 (FoxP3) natural or constitutive regulatory T
cells (Tregs) play an essential role in homeostatic regulation as
FoxP3 Treg-deficientmice (scurfy) die of inflammatory disease by
3weeks after birth (13). The intracellular SOCS proteins, particu-
larly SOCS1, similarly play an indispensible role in such disorders.
In this regard, SOCS1 knockout (SOCS1 / ) mice uniformly
suffer neonatal death by 3weeks after birth, similar to the case
for FoxP3 Treg deficiency, with unregulated IFNγ playing the
central role in the malignant inflammation that is responsible for
the fatal outcome (9). Thus, despite their absolute requirement
for normal development, there has been little interest concerning
the possibility of cross-talk between Tregs and SOCS1. Intuitively,
it would seem that such communication is necessary; otherwise,
one should expect difficulties in terms of maintaining lymphocyte
homeostasis.
We and others have recently shown that SOCS1 and FoxP3
Tregs do indeed interact in such a way that is particularly ben-
eficial to Tregs. Specifically, SOCS1 /  mice were deficient in
peripheral Tregs despite enhanced thymic development (10–
12). Adoptive transfer of CD4+ T lymphocytes that express the
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FIGURE 1 | Development of SOCS1 mimetic and antagonist. Peptides
corresponding to SOCS1-KIR, SOCS1-KIR (53–68), and pJAK2 activation
loop, pJAK2(1001–1013), interact with each other, demonstrating
complementarity. They also interact with the cognate SOCS1 and pJAK2
proteins, respectively, and inhibit pJAK2 and SOCS1 functions, resulting in
either suppressed or enhanced immune response.
SOCS1 gene or parental administration of the SOCS1 mimetic
SOCS1-KIR each induced significant but short-term survival
of SOCS1 /  mice. However, adoptive transfer of the CD4+ T
cells combined with administration of SOCS1-KIR to SOCS1 / 
neonatal mice resulted in increased survival long term (12). In
contrast to the periphery, FoxP3 expression in thymic lympho-
cytes was similar in wild-type and SOCS1 /  mice. Consistent
with increased survival, combined CD4+/SOCS1-KIR treatment
resulted in decreased leukocyte organ infiltration, reduction in
serum IFNγ, and enhanced accumulation of FoxP3 Tregs in
SOCS1 /  mice. These data suggest that SOCS1 is required for
normal peripheral FoxP3 Treg function, and in fact may play a
hierarchical role in SOCS1/Treg cross-talk as stable expression of
FoxP3 in Tregs is dependent on SOCS1 in these cells (14).
Consistent with the above, it has been shown that SOCS1 / 
Tregs produce high levels of IFNγ and rapidly lose FoxP3 when
transferred into immunodeficient Rag2 /  mice or when cul-
tured in vitro (14). The SOCS1 /  Tregs showed hyperactiva-
tion of transcription factors STAT1 and STAT3, and it has been
proposed that such activation is responsible for Treg instability
and loss of suppressive functions (14). How STAT activation is
mechanistically linked to loss of FoxP3 and Treg instability is,
however, not known.
There is evidence that a subset of Treg cells can convert to a T
helper 1 (Th1) or T helper 17 (Th17) phenotype under inflam-
matory and autoimmune conditions (26). Th1 and/or Th17 cells
are the effectors in such diseases as type I diabetes and multiple
sclerosis (MS) (17, 27). Thus, Treg cells may initially respond to
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control an inflammatory or autoimmune state but then undergo
conversion and actually exacerbate the condition. Focus on the E2
ubiquitin-conjugating enzyme Ubc13 has provided some insight
into Treg plasticity (26). Ubc13 is involved in the formation and
conjugation of lysine 63-linked polyubiquitin chains to phos-
phorylated inhibitor of NF-κB (IκB) where phosphorylation is
mediated by IκB kinase (IKK) (26). IκB is then separated from
NF-κB, freeing NF-κB to carry out specific transcription. Mice
that had Ubc13 specifically ablated or knocked out in Treg cells
suffered from systemic autoimmunity with reduction in weight
and inflammatory lymphocyte infiltration of the heart, kidney,
liver, and lung. Ubc13-deficient Treg cells were shown to be capa-
ble of causing the autoimmune condition. Related to this, Ubc13-
deficient Treg cells were defective in SOCS1 and IL-10 induction.
Reporter gene assays showed that active NF-κB was required for
SOCS1 induction but Ubc13 ablated cells lacked active NF-κB
because of lack of an effect on IκB. Treatment of cells with the
SOCS1mimetic SOCS1-KIR suppressed IL-17 production in cells
from Ubc13-deficient mice. Further, loss of weight and a normal
T cell profile were partially restored in SOCS1-KIR treated mice.
This study thus showed that Ubc13 plays a critical role in prevent-
ing Treg cells from undergoing harmful phenotype changes and
that Ubc13 regulated downstream signaling via SOCS1 is key to
maintaining Treg cell homeostasis. Translationally, it suggests a
role for SOCS1 mimetics in treating inflammatory and autoim-
mune diseases where Ubc13-like dysregulation may be involved.
SOCS1, regulatory T cells, the programed death-1 (PD-1), and
T-lymphocyte-associated protein 4 (CTLA-4) immune mediators
are all involved in negative modulation of the immune response.
As was shown above with SOCS1 and Tregs, it appears that all of
these regulatory players including SOCS1 are interconnected and
interdependent, probably in complex ways. It was recently shown,
for example, that there is cross-talk between SOCS1 and PD-1,
where siRNA silencing of SOCS1 expression resulted in inhibition
of PD-1 upregulation (28). Similarly, CTLA-4 has been shown to
be a key effector molecule in Treg function (29, 30). The modula-
tory effect of SOCS1mimetic and antagonist on Tregs, thus, prob-
ably extends to an effect on these other players in positive and neg-
ative regulation of immune function (see Figure 1 for example).
In principle, this suggests a global approach to positive and nega-
tive regulation of immune functions via the SOCS1 mimetic and
antagonist. Currently, specific reagents are used to attack various
players such as PD-1 and CTLA-4 for enhancement of immune
system against cancer (31). Theoretically, the SOCS1 antagonist
should affect these molecules along with its effects on Tregs.
Effect of SOCS1-KIR in Autoimmunity: The
Experimental Allergic Encephalomyelitis
Model As Well As Other Autoinflammatory
Disease Models
In the study of the possible role of SOCS1 and/or SOCS3
in the therapeutic efficacy of IFNβ in the treatment of
relapsing–remitting MS, astrocytes treated with IFNβ showed
upregulation of SOCS1 and SOCS3 (32). This upregulation was
due to the corresponding activation of STAT1α and STAT3 by
SOCS1 and SOCS3, respectively. The chain of events affected
chemokine production and lymphocyte infiltration of the central
nervous system (CNS). Given that IFNβ is an effective therapeutic
for relapsing–remitting MS (33, 34), it is possible that SOCS1
and SOCS3 play an important role in the effectiveness. In a
model of Th17-mediated experimental allergic encephalomyelitis
(EAE), the loss of SOCS1 in T cells resulted in increased IFNγ
activity and a shift of the T cell population from Th17 to Th1,
thus alleviating the EAE (35). In our mouse model of EAE where
both Th1 and Th17 cells were involved, loss of SOCS1 from T
cells did not protect from EAE (17). Specifically, quantitative
reverse transcription polymerase chain reaction (qRT-PCR)
results for SOCS1 and SOCS3 mRNA profiles in CNS infiltrating
T cells showed a complex pattern. For example, SOCS1 mRNA
levels were absent, while SOCS3 levels were modestly increased.
By comparison, splenic CD4+ T cell profiles of mRNA were
modest for both SOCS1 and SOCS3. Significantly, non-CD4+
monocytic cells showed a high level of SOCS3 in the CNS
relative to that of SOCS1. Thus, endogenous SOCS may help
control cells like macrophage, microglia, or dendritic cells in
the CNS, while the infiltrating effector T cells, not dependent
on the accessory cells (36), may be little affected due to the
absence of endogenous SOCS1 and/or SOCS3. SOCS mimetics
could potentially augment or replace the reduced endogenous
SOCS activity of CNS infiltrating lymphocytes and thus have a
therapeutic effect in EAE.
We have shown that the Tkip SOCS1 mimetic is therapeutic
against relapsing–remitting EAE in mice, dampening both the
cellular and humoral immune responses against myelin basic
protein (MBP) (37). In a more comprehensive study of treating
EAEmice with SOCS1-KIR, we similarly showed SOCS1mimetic
therapeutic protection (17). Mice had lymphocyte infiltration of
the CNS at the beginning of treatment, but such infiltration was
cleared after 3weeks of treatment. Both CD4+Th1 and Th17 cells
were suppressed, as well as the IFNγ and IL-17A cytokines are,
respectively, associated with them.We further showed for the case
of Th17 cells that the polarizing cytokine IL-23 was inhibited by
SOCS-KIR. There is evidence that Th1 and Th17 cells function
cooperatively in the pathology of EAE where Th1 cells compro-
mise the blood–brain barrier (BBB) and facilitate infiltration by
Th17 cells (38, 39). The restoration of a pathologic brain to a
normal state by SOCS1-KIR in our EAE model is consistent with
its inhibitory effects on both the Th1 and Th17 arms of EAE and
possibly MS.
SOCS1-KIR or its analogs also show promise in other autoim-
mune and/or inflammatory disorders. Psoriasis is an autoinflam-
matory disorder of the skin that involves interaction between cells
of the immune system with keratinocytes of the skin [reviewed
in Ref. (40)]. Both the innate and adaptive immune systems
play a role in the pathogenesis of psoriasis. Under homeostatic
conditions, microbial attack of the skin results in activation of
innate immune cells such as dendritic cells, which produce the
interleukins 12 (IL-12) and 23 (IL-23), which are involved in the
activation of Th1 and Th17 cells, respectively. Keratinocytes in
their capacity as innate immune cells play a role in dendritic cell
activation as per their production of IL-1, IL-6, and tumor necrosis
factor α (TNFα). Th1 and Th17 cells in turn act on keratinocytes
via IFNγ (Th1) and IL-17A and F (Th17). This further activates
the keratinocytes to produce chemokines, interleukins, and other
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proteins that have both direct and indirect effect on the microbial
insult. Psoriasis is thought to develop because of a dysregulated
feedback loop between the innate and adaptive immune sys-
tems. Psoriasis can be controlled but the dysregulation cannot be
converted back to the homeostatic state.
An understanding of the role of SOCS1 and/or SOCS3 in the
pathogenesis of psoriasis is in its infancy. It has been reported that
keratinocyteswith deleted SOCS3, but not SOCS1 inmice resulted
in psoriasis-like skin pathology (41). Others have reported that
SOCS1 plays a key role in Th1 and IFNγ-induced form of
psoriasis-like skin disorder in experiments where human ker-
atinocytes were transiently transfected with SOCS1 genes (42).
Treatment of human keratinocytes or human skin explants
with IFNγ in an experimental setting produced an inflammatory
pattern similar to that of psoriasis with JAK2 involvement in acti-
vation of STAT1α (43). This in turn induced the epidermal expres-
sion of the integrin ICAM-1, HLA-DR MHC, and chemokines
CXCL10 and CCL2. Immunohistochemically, the IFNγ-treated
explantswere similar to those frompsoriasis patients. The SOCS1-
KIR mimetic analog significantly blocked STAT1α activation as
well as expression of the integrin, MHC, and chemokines. It was
proposed that the SOCS mimetic was a potential therapeutic for
psoriasis (43).
Obesity is a major problem in the United States as well as
the world at large (44). It is associated with a condition called
metabolic syndrome, which is characterized by insulin resistance
reviewed in Ref. (45). The adipose tissue associated with the
metabolic syndrome fuels the activation of macrophages, which
in turn play a major role in the systemic inflammation that
affects key tissues and organs such as the liver. The inflammatory
cytokines that result from the systemic inflammation cause insulin
resistance by inhibiting insulin receptor substrates (IRSs) activity,
which are the mediators of insulin signaling via interaction with
the insulin receptor tyrosine kinase.
SOCS1 and SOCS3 have been shown to play a paradoxical
role in insulin activity in type 2 diabetes. Evidence suggests that
these SOCS dampen the inflammatory response associated with
metabolic syndrome and thus play a role in increasing insulin sen-
sitivity (45). The flip side of this is that SOCS1 (as well as SOCS3)
is also associated with insulin resistance via its competition with
IRS 1 and 2 for binding sites on the insulin receptor, through its
targeting of IRS1/2 and insulin receptor for proteasomal degrada-
tion, and through its inhibitory effect on insulin receptor and JAK
kinase activities (46–49).
A recent quite interesting use of SOCS1-KIR was in the treat-
ment of streptozotocin-induced diabetes in a mouse model (27).
SOCS1 mimetic was particularly effective in reducing vascular
plaque accumulation of lipid, macrophages, and T cells. The
atheroprotective effect was accompanied by systemic reduction
in proinflammatory Ly6Chigh monocytes as well as local reduc-
tion in aorta expression of chemokines and cytokines. Thus,
SOCS1-KIR and other related SOCS mimetics have therapeutic
potential to retard the vascular problems associated with diabetes
(27). Unlike SOCS1, SOCS1-KIR lacks the ability to target IRS
for proteasomal degradation, since it lacks the required SOCS
box (3). This could possibly play a role in its effectiveness in
reducing the vascular inflammation in the mouse model of dia-
betes (27).
Broad Antiviral Activity of SOCS1
Antagonist
There is a constitutive presence of IFNβ (50, 51) and SOCS1
(19) in cells. The constitutive IFNβ plays a key role in opti-
mizing the activity of induced types I and II IFNs (19, 50, 51).
At the same time, the constitutive IFNβ as well as induced and
added IFNs are regulated by SOCS1 (19). For example, if we treat
cells with lipo-pJAK2(1001–1013), we decrease constitutive and
induced SOCS1, which in turn increases the levels and activities
of the constitutive, induced, and added IFNs. Our demonstration
that keratinocytes treated with lipo-pJAK2(1001–1013) possessed
enhanced antiviral activity against HSV-1 (25) supported our
suppositions about antiviral activity, particularly in vivo, against
disparate viruses such as vaccinia virus (19) and encephalomy-
ocarditis virus (EMCV) (19) described below in a stringent test
of broad, effective antiviral activity.
Vaccinia Virus
Poxviruses are large, complex, double-stranded DNA viruses that
have wrecked havoc on human existence over the ages, because
of their innate ability to neutralize the IFN system (52, 53). The
smallpox virus is historically responsible for some of the most
devastating pandemics in the history of humankind and has been
estimated to cause approximately 500 million deaths globally in
the past century alone (53).Humanmonkeypox virus is a zoonotic
poxvirus with a clinical presentation similar to that of smallpox.
The majority of human monkeypox infections occur in Central
Africa and if a more infectious, virulent variant should arise,
it could represent a health concern and hysteria similar to that
involving the recent Ebola virus epidemic in Africa (54).
The testing of the SOCS1 antagonist in a vaccinia virus poxvirus
model could thus serve two purposes. First, it tests the antiviral
effect of the antagonist. Second, it provides a potential much
needed drug therapeutic to poxvirus infections. We reasoned that
independent of all other therapeutics that the SOCS1 antagonist,
lipo-pJAK2(1001–1013), would tilt the immune balance in mice
infected with a lethal dose of vaccinia virus toward a more vig-
orous IFN and innate protective immune response against the
virus (19). Antagonist protected mice as shown in Figure 2 in a
FIGURE 2 | SOCS1 antagonist is an effective therapeutic for lethal
intranasal vaccinia virus infection of C57BL/6 mice.
Lipo-pJAK2(1001–1013), pJAK2 at 10 µg (), 50 µg (H), or 200 µg () was
injected intraperitoneally on days  2,  1, and 0, relative to virus challenge.
Lipo-JAK2(1001–1013)2A (JAK2A) has alanine substituted for tyrosines at
1007 and 1008, and is an inactive control. For details, see Ref. (19).
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dose-dependent fashion with complete protection at 200 µg
lipo-pJAK2(1001–1013), while controls succumbed to virus by
day 9.
The question arises as to whether the SOCS antagonist inhibits
virus replication or virus spread. Accordingly, vaccinia virus sus-
ceptible cells were treated with lipo-pJAK2(1001–1013) at a final
concentration of 50 µM and then challenged with a dose of virus
that ensured that all of the cells were infected at the same time,
resulting in a one-step growth curve. Lipo-pJAK2(1001–1013)
inhibited virus replication by approximately 92% as determined
by intracellular virus yield when compared to the control variant
lipo-pJAK2(1001–1013)2A. Inhibition was approximately 83% as
determined by extracellular virus yield. Thus, SOCS1 antagonist
inhibited vaccinia virus replication and not simply its release
from the cells. This observation is in stark contrast to inhibition
of vaccinia virus release but not replication from cells by two
different tyrosine kinase inhibitors (55, 56). Thus, the SOCS1
antagonist inhibited vaccinia virus replication and not simply its
release, the latter being less reliable in protecting infected mice.
Encephalomyocarditis Virus
Encephalomyocarditis virus is a plus strand rodent picornavirus
but is capable of infecting other species including humans (57).
Treatment of L929 fibroblasts with the SOCS1 antagonist at 24 µM
prior to infection with EMCV (200 PFU) inhibited EMCV growth
by approximately 50% (19). The antagonist variant, by contrast,
was only 7% protective. In vivo studies involved treatment of
C57BL/6 mice with 50, 100, or 200 µg lipo-JAK2(1001–1013)
every other day beginning at day 2 and resulted in 60–80% pro-
tection at the higher doses. Variant lipo-pJAK2(1001–1013)2A by
contrast, was not protective at 200 µgwith the death of all themice
by day 5. The extent of protection by the antagonist is remarkable,
given the aggressive virulence of EMCV in these experiments.
Thus, the SOCS1 antagonist is protective against EMCV as well
as against vaccinia virus.
Conclusion
As key as SOCS proteins such as SOCS1 are to normal immune
and non-immune functions, they do not lend themselves to
controlled and practical manipulation to restoration of home-
ostasis in autoimmune and inflammatory disorders. Intrinsically
disordered proteins (IDPs) and IDP regions lack stable tertiary
structure but are responsible for numerous biological functions,
particularly those associated with signaling, transcription, DNA
interactions, and cellular division and differentiation (58, 59). We
took advantage of this important aspect of protein function in
our development of small peptide SOCS1 mimetics based on the
KIR region of SOCS1.We similarly developed a SOCS1 antagonist
based on the activation loop of JAK2, which is the target of the
KIR of SOCS1. We view these peptide mimetics and antagonists
as templates of a larger and more general approach to develop-
ment of mimetics and antagonists of other molecules involved in
signaling.
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